Regina K. Egan

Massachusetts General Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index3.7kcitations120works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(29), Cholangiocarcinoma and Gallbladder Cancer Studies(25), Biochemical and Molecular Research(22), Lung Cancer Treatments and Mutations(21), Cancer, Hypoxia, and Metabolism(18)

Publications120 total

Supplementary Fig. S5 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S1 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S3 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Suppl. Tab. 1 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S4 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S6 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Suppl. Tab. 2 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S7 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Supplementary Fig. S2 from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Data from Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
2025Open Access
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
Molecular Cancer Therapeutics·2025· 1 citedOpen Access
A landscape of response to drug combinations in non-small cell lung cancer
Nature Communications·2023· 52 citedOpen Access
Figure S8 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
Data from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
2023Open Access
Figure S7 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
Figure S6 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
Figure S9 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
Figure S1 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
Supplementary Table from EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
2023Open Access
Figure S10 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Cyril H. Benes(50), Patricia Greninger(44), Ellen Murchie(18), Leah J. Damon(15), Mathew J. Garnett(12), Joseph McClanaghan(12), Nabeel Bardeesy(12), Aaron N. Hata(11), John D. Gordan(11), Lipika Goyal(11), Andrew X. Zhu(11), Ultan McDermott(10), Supriya K. Saha(10), Andrew S. Liss(10), Kevan M. Shokat(10), Giovanna Stein Crowther(10), Giovanna T. Stein(9), Benjamin P. Kleinstiver(9), Mortada S. Najem(9), Yasutaka Kato(9)